white → blue1 → blue1 → blue2
3-MeO-PCMo
4-[1-(3-Methoxyphenyl)cyclohexyl]morpholine
PCMo
3-MeO-PCMo is a dissociative anesthetic of the arylcyclohexylamine class, specifically a morpholine analogue of 3-MeO-PCP.1 It functions as an NMDA receptor antagonist and sigma receptor agonist, producing a state of dissociative anesthesia. Notably, it possesses less than one-tenth the potency of its parent compound 3-MeO-PCP.2 It has appeared on the research chemical market as a designer drug1 with very limited data regarding its safety profile or long-term effects.
Dosage & Duration
Dosage
Threshold~50 mg
Light50-80 mg
Moderate80-125 mg
Strong125-150 mg
Heavy150+ mg
Duration
Onset30-60 minutes
Peak2-3 hours
Offset1-2 hours
After Effects2-3 hours
Total5-6 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of MXE and ketamine.
Visual
This substance does not enhance visual stimuli; instead, it tends to degrade and decrease visual aptitude in a variety of ways.
Geometry
The visual geometry of 3-MeO-PCMo can be described as very dark and bland when compared to that of ketamine or DXM. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
Suppressions
Auditory
Pharmacology
Pharmacodynamics
3-MeO-PCMo is thought to act primarily as an NMDA receptor antagonist, though direct pharmacological characterization remains limited and this attribution is largely inferred from its structural relationship to other arylcyclohexylamines such as PCP and 3-MeO-PCP. In a functional drebrin cluster assay measuring inhibition of NMDA receptor-stimulated activity, 3-MeO-PCMo demonstrated an IC50 of 26.67 μM, considerably less potent than PCP (2.02 μM) or 3-MeO-PCP (1.51 μM).2 Activity at sigma receptors has also been attributed to the substance, though specific binding data is not available.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of 3-MeO-PCMO and the metabolism of 3-MeO-PCMO is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
DepressantsPsychedelicsStimulants
Tolerance
Full Tolerance
Develops with prolonged and repeated use, necessitating increasingly larger doses to achieve equivalent effects.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateChronic use can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence.3 Compulsive redosing is reported as a notable cognitive effect.
Physical
LowWhen addiction has developed, cravings and withdrawal effects may occur if usage is suddenly stopped, though the specific nature and severity of physical withdrawal has not been well characterized.
Toxicity
Urinary System
Repeated heavy use, particularly on a daily or weekly basis, can cause bladder and urinary tract problems similar to those seen with ketamine but potentially more severe due to the compound's lower potency requiring larger quantities to achieve equivalent effects; symptoms include urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence.
Psychosis Risk
Mania is listed among potential cognitive effects. As with other dissociatives, there is risk of adverse psychological reactions including anxiety, mania, delusions, and psychosis, with these risks increasing at higher doses.
History & Culture
3-MeO-PCMo is a novel dissociative substance that emerged on the gray market as a designer drug in the mid-2010s. It became available primarily through online research chemical vendors, where it was marketed alongside other novel arylcyclohexylamines.1 As a relatively…
Legality
International
3-MeO-PCMo is not named in the official schedules inspected for the 1961 Single Convention, the 1971 Convention, or the 1988 Convention tables. The distinct substance 3-methoxyphencyclidine is listed in Schedule II of the 1971 Convention, but that listing identifies the piperidine compound and does not cover 3-MeO-PCMo. No international class provision in these schedules supplies coverage for the morpholine compound.
By Country
ArgentinaIllegal (analog/blanket ban)Annex II arylcyclohexylamines
3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) fits Argentina's Annex II arylcyclohexylamine group: the phenyl ring bears a permitted methoxy substituent and the amino group may be replaced by 4-morpholinyl. Article 2 of Decree 560/2019 treats substances included in Annex II chemical groups as estupefacientes under Criminal Code article 77. Decree 122/2026 replaced only Annex I, leaving this Annex II group-control basis intact.
BelgiumNot scheduledAnnex IV absent
The Belgian medicines regulator's current Annex IV consolidation lists eight defined generic classes in Annex IVa; 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine does not match any of them. Annex IVb separately names related methoxy-PCP/PCE substances, but not 3-MeO-PCMo or its systematic name; the regulator identifies the Official Gazette annexes and amendments as the legally authoritative texts, while providing this current consolidation as a non-binding aid. No Belgium-specific primary source located in this search schedules the exact morpholine compound or establishes an analogue/blanket rule that covers it.
DenmarkRestrictedList B controlled
3-MeO-PCMo is expressly named as 4-(1-(3-Methoxyphenyl)cyclohexyl)morpholin in Denmark's List B of euphoric substances. The Danish Medicines Agency states that List B substances may only be used for medical and scientific purposes; its 2020 notice further says that, from 27 June 2020, the newly listed substances may only be handled with Agency permission, with import/export requiring a certificate. The current Agency list identifies the annex to BEK no. 405 of 26 March 2026 as the controlling list for substances under control in Denmark.
GermanyIllegal (analog/blanket ban)Arylcyclohexylamine class
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production and import with intent to distribute, administration to others, and trading are punishable offenses.22 Possession is technically illegal but not subject to criminal penalties.
UkraineIllegalTable I List 2
Ukraine expressly lists 3-MeO-PCMo with the exact systematic name 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine in Table I, List No. 2 of its controlled-substances list. The Cabinet of Ministers' 2019 amendment added that exact entry to List No. 2; the current consolidated Resolution No. 770 continues to return the same entry. Table I, List No. 2 is the list of especially dangerous psychotropic substances whose circulation is prohibited.
AustriaIllegal (analog/blanket ban)Anlage II Z 8
3-MeO-PCMo is the exact substance 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine. Austria's NPSV treats substances covered by the chemical definitions in Annex II as new psychoactive substances. The existing finding places this exact arylcyclohexyl compound under Annex II item 8's class definition, rather than transferring a finding for 3-MeO-PCP.
CanadaIllegal (analog/blanket ban)PCP analogues
Controlled Drugs and Substances Act, Schedule I14
3-MeO-PCMo is a morpholine analogue of phencyclidine rather than 3-MeO-PCP. Schedule I controls phencyclidine, its derivatives and analogues, including salts of derivatives and analogues. The statutory analogue category therefore covers this phencyclidine analogue.
FinlandRestrictedConsumer-market prohibited
Government Decree 1130/2014 on psychoactive substances prohibited from the consumer market, as amended by Government Decree 638/20201819
Exact 3-MeO-PCMo is expressly listed under its systematic name in the annex amended by Government Decree 638/2020. This is a consumer-market prohibition, not a narcotics scheduling or analogue-coverage claim.
SwitzerlandControlled (Verzeichnis E)Citation needed
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation. Production, distribution, and possession without authorization are prohibited.
United KingdomIllegalPsychoactive substance
3-MeO-PCMo is subject to the Psychoactive Substances Act 2016 where it is capable of producing a psychoactive effect and is not an exempted substance. The Act prohibits producing, supplying, offering to supply, importing, and exporting such a substance, while the general possession offence is limited to custodial institutions.
References
Source Pages
Citations
- Tristan Colestock, Jason Wallach, Mohammed Mansi, Nasser Filemban, Hamilton Morris, Simon P. Elliott, Folker Westphal, Simon D. Brandt, & Adeboye Adejare. (February 2018). Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Testing and Analysis, 10(2), 272–283. https://doi.org/10.1002/dta.2213123
- Toshinari Mitsuoka, Katsuhiko Hanamura, Noriko Koganezawa, Ruri Kikura-Hanajiri, Yasufumi Sekino, & Tomoyuki Shirao. (September–October 2019). Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay. Journal of Pharmacological and Toxicological Methods, 99, Article 106583. https://doi.org/10.1016/j.vascn.2019.1065831234
- Arvie Abiero, Chrislean Jun Botanas, Raly James Custodio, Leandro Val Sayson, Mikyung Kim, Hyun Jun Lee, Hee Jin Kim, Kun Won Lee, Youngdo Jeong, Joung-Wook Seo, In Soo Ryu, Yong Sup Lee, & Jae Hoon Cheong. (March 2020). 4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels. Psychopharmacology, 237(3), 757–772. https://doi.org/10.1007/s00213-019-05412-y1
- Abbas Ahmadi, Mohsen Khalili, Ramin Hajikhani, & Moslem Naserbakht. (April 2011). New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats. Pharmacology, Biochemistry, and Behavior, 98(2), 227–33. https://doi.org/10.1016/j.pbb.2010.12.0191
- Decree 560/2019, Annex II (Arilciclohexilaminas). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-560-2019-326675/texto1
- Decree 560/2019, Annex II (Arilciclohexilaminas). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/326675_dec560-2_pdf/archivo1
- Decree 560/2019, Annex II (Arilciclohexilaminas). argentina.gob.ar (n.d.). https://www.argentina.gob.ar/normativa/nacional/decreto-122-2026-423520/texto1
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV). ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=200076421
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV). pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/compound/1326059081
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IV. famhp.be (n.d.). https://www.famhp.be/en/human_use/particular_products/specially_reglemented_substances/narcotics_psychotropics/legislation_substances1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IV. famhp.be (n.d.). https://www.famhp.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IV. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- Controlled Drugs and Substances Act, Schedule I. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95314.html1
- Bekendtgørelse om euforiserende stoffer (BEK nr. 405 af 26/03/2026). retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2026/405/dan/pdf1
- Bekendtgørelse om euforiserende stoffer (BEK nr. 405 af 26/03/2026). laegemiddelstyrelsen.dk (n.d.). https://laegemiddelstyrelsen.dk/da/godkendelse/virksomhedstilladelse-og-registrering/euforiserende-stoffer/liste-over-stoffer/1
- Bekendtgørelse om euforiserende stoffer (BEK nr. 405 af 26/03/2026). laegemiddelstyrelsen.dk (n.d.). https://laegemiddelstyrelsen.dk/da/nyheder/2020/bekendtgoerelse-om-euforiserende-stoffer-ny-hovedbekendtgorelse-og-26-nye-stoffer-tilfoejet/1
- Government Decree 1130/2014 on psychoactive substances prohibited from the consumer market, as amended by Government Decree 638/2020. finlex.fi (n.d.). https://www.finlex.fi/fi/laki/alkup/2020/202006381
- Government Decree 1130/2014 on psychoactive substances prohibited from the consumer market, as amended by Government Decree 638/2020. finlex.fi (n.d.). https://finlex.fi/fi/lainsaadanto/2014/11301
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 6; § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1 Nr. 6; § 3. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- Neue-psychoaktive-Stoffe-Gesetz (NpSG) — gesetze-im-internet.de. (n.d.). https://www.gesetze-im-internet.de/npsg/BJNR261510016.html1
- Cabinet of Ministers of Ukraine Resolution No. 770 of 6 May 2000. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/go/600-2019-%D0%BF1
- Cabinet of Ministers of Ukraine Resolution No. 770 of 6 May 2000. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/go/770-2000-%D0%BF/en/ed202506131
- Psychoactive Substances Act 2016, sections 2 and 4. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/21
- Psychoactive Substances Act 2016, sections 2 and 4. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/2016/2/section/41
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCMo article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.